Adding Yervoy to Opdivo Increases Responses in Some Ovarian Cancer Patients, Phase 2 Study Shows
News
A combination of Opdivo (nivolumab) and Yervoy (ipilimumab) leads to better response rates in patients with persistent or recurrent ovarian cancer than Opdivo alone, a Phase 2 study shows. The ... Read more